Advantage Alpha Capital Partners LP Sells 11,651 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Advantage Alpha Capital Partners LP cut its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 34.2% during the 3rd quarter, Holdings Channel reports. The fund owned 22,379 shares of the biopharmaceutical company’s stock after selling 11,651 shares during the period. Advantage Alpha Capital Partners LP’s holdings in TG Therapeutics were worth $523,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of TGTX. Oppenheimer & Co. Inc. acquired a new position in shares of TG Therapeutics during the third quarter valued at about $759,000. Segall Bryant & Hamill LLC bought a new position in TG Therapeutics in the third quarter worth approximately $1,225,000. Principal Financial Group Inc. grew its stake in TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after acquiring an additional 725,371 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of TG Therapeutics during the second quarter valued at approximately $8,698,000. Finally, Marshall Wace LLP acquired a new position in shares of TG Therapeutics during the second quarter worth approximately $36,501,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on TGTX shares. JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday. TD Cowen assumed coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. B. Riley boosted their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. The Goldman Sachs Group upped their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, HC Wainwright raised their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 10.50% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $34.26 on Wednesday. TG Therapeutics, Inc. has a 12 month low of $12.30 and a 12 month high of $36.84. The stock has a market capitalization of $5.33 billion, a P/E ratio of -342.60 and a beta of 2.19. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm’s 50 day moving average is $25.81 and its 200 day moving average is $21.83.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.73 earnings per share. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.